1 / 64

Cardiovascular Medicine For Finals

Cardiovascular Medicine For Finals. Outline. ECG’s Arrhythmias Acute coronary syndromes Heart failure Infective Endocarditis Cardiomyopathies Valvular heart disease. ECG approach. Patient details Calibration Rate Rhythm Axis P waves QRS complex ST complex. ECG values. Values:

pattym
Télécharger la présentation

Cardiovascular Medicine For Finals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cardiovascular Medicine For Finals

  2. Outline • ECG’s • Arrhythmias • Acute coronary syndromes • Heart failure • Infective Endocarditis • Cardiomyopathies • Valvular heart disease

  3. ECG approach • Patient details • Calibration • Rate • Rhythm • Axis • P waves • QRS complex • ST complex

  4. ECG values Values: • PR interval: 120-200ms (3-5 small squares of ECG paper) • QRS complex: less than 120ms (3 small squares) • QT interval (upper limit of normal is 450ms in men and 470ms in women)

  5. Myocardial infarction: • ST elevation definition: • More than 2 mm’s of elevation in two congruent chest leads or more than 1mm ST elevation in two congruent limb leads • Myocardial infarction definition: - 2 of 3 from: Chest pain, ECG changes, Trop rise

  6. ECG – coronary artery territories

  7. Common Arrhytmias

  8. Atrial fibrillation • Causes: • Ischaemic heart disease • Valvular disease • Hypertension • Hyperthyroidism • Electrolyte imbalances • Sepsis

  9. Rhythm vs rate control Cardio-vert if: • Less than 65 • AF for less than 48 hours • Structurally normal heart Otherwise: • Rate control with a beta blocker • If contra-indications to beta blocker or LV impairment then use digoxin (as positively inotropic)

  10. CHA2DS2VASC Latest ESC guidance: 0 = No treatment 1 = Consider oral anticoagulant (warfarin) 2 or more = warfarin No role for aspirin in the current guidance http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines_Focused_Update_Atrial_Fib_FT.pdf C = 1 for congestive heart failure (EF<35%) H = 1 for hypertension A = 2 if > 75 D = 1 if diabetic S = 2 if previous stroke, TIA or systemic emboli V = 1 if previous MI, PVD or aortic plaque A = 1 if age 65-74 S = 1 if female c

  11. Anti-arrhythmic medications • Some Block Potassium Channels Class 1: Sodium channel blockers Class 2: Beta blockers Class 3: Potassium channel blockers Class 4: Calcium channel blockers Digoxin and Adenosine

  12. Class I • 1A: Quinidine, procainamide, disopyramide Prolong action potential and are used for SVT’s and VT’s Side effects: N & V, anti-cholinergic, Hypotension, precipitate SLE • 1B: Lignocaine, tocainide Shorten the action potential and used in VT’s Side effects: Convulsions, N & V • 1C: Flecainide Slow conduction speed and used in SVT’s and VT’s Side effects: Arrhythmias & dizziness

  13. Class II • Eg. Propanolol and atenolol block the increase in pacemaker activity that is produced by sympathetic stimulation of B-adrenoreceptors • Used for ectopic beats, AF and atrial tachycardia • Side effects: Tiredness and asthma NB. Sotalol ad bretylium have both class II and III actions

  14. Class III • Eg. Amiodarone block K+ channels slowing repolarisation leading to a prolonged action potential and refactory period • Used in SVT’s and VT’s • Side effects: Photosensitivity, Blue/grey skin discolouration, Liver toxicity, Thyroid disorders, Neuropathy, Pulmonary alveolitis

  15. Class IV • Eg. Verapamil block Calcium channels thereby decreasing spontaneous activity at both the SA and AV node • Used for SVT’s • Side effects: Precipitation of cardiac failure, AV block and constipation

  16. Class V • Digoxin: Used for SVT’s especially AF Side effects: N & V, green-yellow vision, blurred vision, confusion, heart block, gynaecomastia NB. Potentiated by Hypokalaemia • Adenosine: Used to terminate SVT’s

  17. Acute coronary syndromes

  18. Acute coronary syndromes • ST elevation myocardial infarction (ST elevation or new LBBB), non-ST elevation myocardial infarction, or unstable angina • Symptoms: Chest pain or tightness radiating to the jaw or left arm. May be associated with sweating, nausea and vomiting or shortness of breath

  19. Treatment R = Reassurance O = Oxygen (15 litres non-rebreathe mask) M = Morphine A = Aspirin (300mg) N = Nitrates C = Clopidogrel (300mg – some centres 600 if for angioplasty) E = Enoxoparin (This trust clexane 2.5mg S/C)

  20. STEMI and Non-STEMI • STEMI: once confirmed should be for PCI with the ACA recommending less than 90mins for door to PCI time. (If PCI not available: thrombolysis within 30 mins) • NSTEMI: ACS protocol of aspirin, clopidogrel and LMWH. 12 hour trop which if positive warrants urgent coronary angiography (ie. Next elective list)

  21. TIMI Score - Age > 65 • Aspirin in last 7 days • At least 2 episodes of angina in last 24 hours • ST deviation (elevation or depression) of at least 0.5mm on ECG • Elevated Trop • Known CAD • At least 3 risk factors • Scores risk of MI and death and informs treatment

  22. Heart Failure

  23. Heart Failure • Broadly divided in 2 categories: • Those that damage cardiac muscle (eg IHD and cardiomyopathies) • Those that demand extra work of the heart (eg systemic hypertension, valvular heart disease)

  24. Pathophysiology • Decrease in contractility of the affected heart muscle • This shifts the Starling curve to the right reducing the force of contractility for a given filling pressure • Body attempts to increase filling pressure by: • Catecholamine release: Increasing rate and force • Vasoconstriction: Increases filling pressure • Renal retention of Na and water

  25. Effect of this response • Effective for a while BUT: • Leads to dilatation: which can cause valvular disease • Increases oxygen demand: This predisposes the heart to ischaemia • Downregulation of B-adrenoreceptors: This stops the effect of increased sympathetic drive

  26. Treatment • Heart failure can present as an acute exacerbation ie. Pulmonary oedema (predominantly left sided failure) or chronically with leg swelling (predominantly right sided) • Treatment can be acute ie. Offloading with diuretics and also prognostic

  27. Prognostic treatments

  28. ACE inhibitors • Eg. Enalapril, Lisinopril, and Captopril: • Block production of angiotensin II and therefore aldosterone • Prevent the breakdown of bradykinin • Prolong life in heart failure Produce vasodilation thereby decreasing afterload and subsequent oedema

  29. Beta blocker • The sympatholytic effects of beta-blockers have been shown to be beneficial in the long term management of heart failure • They act by slowing the heart rate and thereby increasing diastolic filling time NB. Not to be used in the treatment of acute heart failure

  30. Spironolactone • Antagonise the effect of aldosterone or block Na channels at the distal tubule • Prevents Na reabsorption and K excretion • Shown to prolong life in heart failure • Main side effect is hyperkalaemia especially when used with ACE inhibitors

  31. Digoxin • Cardiac glycosides inhibit the Na/K pump which leads to a rise in intracellular Ca which: • Increases the force of contraction • Reduces the hearts oxygen consumption • Slows heart rate through vagal effect • Side effects: Anorexia, N & V, Diarrhoea, Confusion, Arrhythmia in toxic doses

  32. Non-drug treatment of heart failure • CRT: Patients with heart failure often have left bundle branch block – this leads to dys-synchrony in the ventricular contraction. Pacemakers that synchronise left and right ventricular function therefore increase cardiac output • ICD’s: Patients with heart failure are prone to malignant arrhythmias. ICD’s can prevent sudden cardiac death • Heart transplantation: With appropriate selection 1 year survival is 80% and 5 year 70%

  33. Endocarditis

  34. Endocarditis • Infection of the endocardium usually involving the heart valves • Usually affects damaged valves and itself damages valves predisposing to future infections • Vegetations (consisting of fibrin, platelets and infecting organism) usually arise on the valves • Sequelae of infective endocarditis include: • Acute valve incompetence • Emboli to spleen, kidneys and brain • Glomerulonephritis and renal failure

  35. Organisms: • Streptococcus viridans: subacute; common after dental procedures, tonsillectomy or bronchoscopy • Staph aureus: acute and common in IVDU’s and indwelling catheters • Enterococcus faecalis: common after pelvic surgery • Coxiella burnetti (Q fever): subacute • Staphylococcus epidermidis, aspergillus, candida, brucella, histoplasma: common in IVDU’s and prosthetic heart valves

  36. Duke criteria

  37. Cardiomyopathies

  38. Cardiomyopathies • 3 types: • Dilated (congestive) cardiomyopathy (85%) with dilated left ventricle and impaired systolic function • Hypertrophic (obstructive) cardiomyopathy (10%) hypertrophy of ventricles partciularly septum – reduced diastolic filling • Restrictive cardiomyopathy (5%): decreased ventricular compliance restricts ventricular filling

  39. Dilated cardiomyopathy • Pathogenic factors include: • Genetic defect • Alcohol toxicity • Postviral myocarditis • Peripartum • Haemochromatosis • Systemic disease (eg. Sarcoid, SLE) • Drug therapy (eg. Cyclophosphamide) etc

  40. Dilated cardiomyopathy • Morphology of cardiomyopathy is: • Cardiomegaly with dilated thin walls in all chambers • Irregular myocyte hypertrophy and fibrosis • Dilated cardiomyopathy can cause heart failure, arrhythmia and emboli • Mortality is 40% in 2 years

  41. Hypertrophic cardiomyopathy • Hypertrophy of ventricles and septum which is often asymmetrical • Causes distorted contraction and an abnormal mitral valve movement • 50% of cases are inherited 9autosomal dominant • Can cause dyspnoea, angina, syncope, and sudden death NB. Death is normally due to ventricular arrhythmias rather than outflow obstruction

  42. Restrictive cardiomyopathy • Restrictive cardiomyopathy is stiffening of the myocardium with restricted ventricular filling. • Often associated with: • Amyloidosis: most common in the West • Endomyocardial fibrosis: children and young adults in Africa • Loeffler’s endocarditis: temperate climates • Symptoms are similar to constrictive pericarditis

  43. Valvular heart disease

  44. 1) Mitral stenosis • Causes: • Rheumatic fever • Congenital eg. Lutembacher’s syndrome • Malignant (carcinoid) • SLE • Left atrial myxoma

More Related